ARTICLE
23 March 2026

PBM Reform 2026: What Recent Legislation Means For The Industry (Video)

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
PBM reform 2026 is reshaping how PBMs and plan sponsors operate, as Congress and federal agencies introduce new compliance requirements and enforcement standards.
United States Food, Drugs, Healthcare, Life Sciences
Theresa C. Carnegie’s articles from Mintz are most popular:
  • within Food, Drugs, Healthcare and Life Sciences topic(s)
Mintz are most popular:
  • within Transport topic(s)

PBM reform 2026 is reshaping how PBMs and plan sponsors operate, as Congress and federal agencies introduce new compliance requirements and enforcement standards. With multiple reforms moving forward at once, many organizations are asking: what changed, what’s required, and what comes next?

Mintz Health Care Law attorneys analyze PBM reforms enacted under the Consolidated Appropriations Act of 2026 (CAA 2026), along with proposed Department of Labor rules, recent FTC enforcement activity, and federal drug pricing initiatives.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More